Reviva Pharmaceuticals to be delisted from Nasdaq May 14, 2026; will trade on OTCQB

REVIVA PHARMACEUTICALS HOLDINGS, INC.

Nasdaq Hearings Panel determined to delist RVPH due to non-compliance with minimum $1.00 bid price rule.
Trading on Nasdaq suspended as of May 14, 2026; stock will quote on OTCQB Venture Market under same symbol RVPH.
Delisting risks include reduced liquidity, fewer investors, penny stock classification, and limited analyst coverage.
Company updated risk factors to reflect additional risks of OTC trading vs. national exchange listing.

item 3.01item 8.01

Source: SEC EDGAR

accession 0001437749-26-016538

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.